This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with wild-type metastatic castration-resistant prostate cancer who are receiving abiraterone or enzalutamide.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499126 | PMC |
| http://dx.doi.org/10.1001/jamaoncol.2019.0869 | DOI Listing |
Publication Analysis
Top Keywords
androgen receptor
8
abiraterone enzalutamide
8
wild-type metastatic
8
metastatic castration-resistant
8
castration-resistant prostate
8
prostate cancer
8
receptor burden
4
burden poor
4
poor response
4
response abiraterone
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!